Ani Pharmaceuticals Inc
ANIPFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Ani Pharmaceuticals Inc Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 17 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 30, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Ani Pharmaceuticals Inc's recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-05-11 · Lalwani Nikhil: Larger than 117 of the 118 other insider sales of Common Stock on file. SEC filing
- 2025-08-21 · Shanmugam Muthusamy: Larger than 115 of the 118 other insider sales of Common Stock on file. SEC filing
- 2025-08-20 · Shanmugam Muthusamy: Larger than 113 of the 118 other insider sales of Common Stock on file. SEC filing
- 2025-08-15 · Shanmugam Muthusamy: Larger than 116 of the 118 other insider sales of Common Stock on file. SEC filing
- 2025-08-14 · Shanmugam Muthusamy: Larger than 112 of the 118 other insider sales of Common Stock on file. SEC filing
- 2025-08-12 · CAREY STEPHEN P.: Larger than 114 of the 118 other insider sales of Common Stock on file. SEC filing
- 2025-08-12 · Lalwani Nikhil: Larger than all 118 other insider sales of Common Stock on file. SEC filing
- 2024-11-26 · Lalwani Nikhil: Larger than 111 of the 118 other insider sales of Common Stock on file. SEC filing
- 2024-07-16 · Shanmugam Muthusamy: Larger than 109 of the 118 other insider sales of Common Stock on file. SEC filing
- 2024-03-06 · Lalwani Nikhil: Larger than 110 of the 118 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-29 | CAREY STEPHEN P. · SVP & CFO | Common Stock | S — Open market or private sale | −2,850 | 84.12 | SEC filing |
| 2026-06-12 | Cook Meredith · SR. VP, GENERAL COUNSEL & SEC. | Common Stock | S — Open market or private sale | −500 | 82.03 | SEC filing |
| 2026-06-08 | HAUGHEY THOMAS · Director | Common Stock | S — Open market or private sale | −2,000 | 80.88 | SEC filing |
| 2026-06-05 | CAREY STEPHEN P. · SVP & CFO | Common Stock | S — Open market or private sale | −3,312 | 80.00 | SEC filing |
| 2026-05-13 | Walsh Patrick D · Director | Common Stock | S — Open market or private sale | −10,000 | 80.63 | SEC filing |
| 2026-05-13 | Cook Meredith · SR. VP, GENERAL COUNSEL & SEC. | Common Stock | S — Open market or private sale | −500 | 78.16 | SEC filing |
| 2026-05-12 | Gutwerg Ori · SVP, GENERICS | Common Stock | S — Open market or private sale | −2,772 | 79.50 | SEC filing |
| 2026-05-12 | Rowland Thomas Andrew · SVP, HEAD - ESTABLISHED BRANDS | Common Stock | S — Open market or private sale | −459 | 79.21 | SEC filing |
Showing 8 of 10 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-05 | CAREY STEPHEN P. · SVP & CFO | Common Stock | M — Exercise or conversion of derivative security | +3,312 | SEC filing |
| 2026-06-05 | CAREY STEPHEN P. · SVP & CFO | Stock Option (right to buy) | M — Exercise or conversion of derivative security | −3,312 | SEC filing |
| 2026-05-21 | TANNENBAUM RENEE P · Director | Common Stock | A — Grant, award, or other acquisition | +4,357 | SEC filing |
| 2026-05-21 | Pera Antonio R · Director | Common Stock | A — Grant, award, or other acquisition | +4,357 | SEC filing |
| 2026-05-21 | HAUGHEY THOMAS · Director | Common Stock | A — Grant, award, or other acquisition | +4,357 | SEC filing |
| 2026-05-21 | Thoma Jeanne · Director | Common Stock | A — Grant, award, or other acquisition | +4,357 | SEC filing |
| 2026-05-21 | Leonard Matthew J · Director | Common Stock | A — Grant, award, or other acquisition | +4,357 | SEC filing |
| 2026-03-07 | Gutwerg Ori · SVP, GENERICS | Common Stock | F — Payment of exercise price or tax by delivering securities | −3,314 | SEC filing |
Showing 8 of 31 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.